These are the published 2020–2026 papers that explicitly include both “fenbendazole” and “prostate cancer”: two prostate-cancer cell-delivery studies and one 2026 institutional use-pattern report noting fenbendazole use among patients with prostate cancer.
Bottom line
The available prostate-cancer-specific published fenbendazole literature is very narrow: two mechanistic/nanodelivery papers in PC-3 prostate cancer cells and one real-world use-pattern study that includes prostate cancer among fenbendazole users.
Confidence level: High — the supplied evidence directly identifies these three papers, and no other retrieved paper explicitly pairs fenbendazole with prostate cancer in the title or abstract.
This does not mean that other information on benzimidazole carbamates designed for human use in treating prostate cancer cells is unavailable. I’ll look into this tomorrow.
There is also a considerable amount of anecdotal information about prostate cancer and fenbendazole available on Dr. Makis’ Substack. https://makisw.substack.com/
References
Olutayo, E., Phan, M.V., Willis, J., Hu, Z.I. (2026) A single institutional experience on patterns of ivermectin and fenbendazole use among patients with gastrointestinal cancers.. Journal of Clinical Oncology. https://doi.org/10.1200/JCO.2026.44.2_suppl.818
Koohi Moftakhari Esfahani, M.K.M., Alavi, S.E., Cabot, P.J., (...), Izake, E.L. (2022) β-Lactoglobulin-Modified Mesoporous Silica Nanoparticles: A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostate Cancer Cells. Pharmaceutics. https://doi.org/10.3390/pharmaceutics14040884
Koohi Moftakhari Esfahani, M.K.M., Alavi, S.E., Cabot, P.J., (...), Izake, E.L. (2021) Pegylated mesoporous silica nanoparticles (Mcm-41): A promising carrier for the targeted delivery of fenbendazole into prostate cancer cells. Pharmaceutics. https://doi.org/10.3390/pharmaceutics13101605